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ABSTRACT
Chondrogenic differentiation of bone marrow-derived mesenchymal stromal/stem cells (MSCs) can
be induced by presenting morphogenetic factors or soluble signals but typically suffers from limited
efficiency, reproducibility across primary batches, and maintenance of phenotypic stability. Consid-
ering the avascular and hypoxic milieu of articular cartilage, we hypothesized that sole inhibition of
angiogenesis can provide physiological cues to direct in vivo differentiation of uncommittedMSCs to
stable cartilage formation. HumanMSCswere retrovirally transduced to express a decoy soluble vas-
cular endothelial growth factor (VEGF) receptor-2 (sFlk1), which efficiently sequesters endogenous
VEGF in vivo, seeded on collagen sponges and immediately implanted ectopically in nude mice. Al-
though na¨ıve cells formed vascularized fibrous tissue, sFlk1-MSCs abolished vascular ingrowth into
engineered constructs, which efficiently and reproducibly developed into hyaline cartilage. The gen-
erated cartilage was phenotypically stable and showed no sign of hypertrophic evolution up to 12
weeks. In vitro analyses indicated that spontaneous chondrogenic differentiation by blockade of an-
giogenesiswas related to thegenerationofahypoxic environment, in turnactivating the transforming
growth factor-b pathway. These findings suggest that VEGF blockade is a robust strategy to enhance
cartilage repair by endogenous or graftedmesenchymal progenitors. This article outlines the general
paradigm of controlling the fate of implanted stem/progenitor cells by engineering their ability to
establish specific microenvironmental conditions rather than directly providing individual morpho-
genic cues. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:1–9
SIGNIFICANCE
Chondrogenic differentiation ofmesenchymal stromal/stemcells (MSCs) is typically targetedbymor-
phogen delivery, which is often associated with limited efficiency, stability, and robustness. This ar-
ticle proposes a strategy to engineerMSCswith the capacity to establish specificmicroenvironmental
conditions, supporting their own targeted differentiation program. Sole blockade of angiogenesis
mediated by transduction for sFlk-1, without delivery of additional morphogens, is sufficient for in-
ducing MSC chondrogenic differentiation. The findings represent a relevant step forward in the field
because the method allowed reducing interdonor variability in MSC differentiation efficiency and,
importantly, onset of a stable, nonhypertrophic chondrocyte phenotype.
INTRODUCTION
Bone marrow-derived mesenchymal stromal/
stem cells (MSCs) have been proposed for cell-
based cartilage regeneration because of their ca-
pacity to differentiate into chondrocytes and
their availability in an autologous setting. The
chondrogenic differentiationofMSCs critically re-
quires the exposure to potent morphogens [1] and
is associated with a large degree of donor-to-donor
variability. In addition, thepreculture ofMSCs in the
presence of chondroinductivemolecules is typically
associated with the onset of a hypertrophic chon-
drocytephenotype, leading tovessel ingrowth,min-
eralization,and remodeling into bone tissue upon
in vivo implantation [2, 3].
During limb development, chondrogenesis of
condensatingmesenchymal cells occurs in the ab-
sence of vasculature. Moreover, the stability of
the chondrocytic phenotype at the articulating
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surfaces of long bones, as opposed to progression of differentia-
tion toward endochondral ossification, is associated with the
maintenance of an avascular environment [4]. Consistent with
these observations, seminal experiments of marrow stromal cells
implanted subcutaneously in diffusion chambers, not allowing
blood vessel ingrowth, found the spontaneous formation of car-
tilage matrix, along with bone-like and fibrous tissue [5].
Vascular endothelial growth factor (VEGF) is the master reg-
ulator of angiogenesis during skeletal growth [6, 7]. VEGF expres-
sion critically regulates cartilage ossification [8] because it is
producedbyhypertrophic chondrocytes at the start of endochon-
dral bone formation, but not by quiescent and proliferating chon-
drocytes at earlier stages. VEGF inhibition prevented vascular
infiltration of hypertrophic cartilage and ossification of the growth
plate during bone elongation [8]. Moreover, systemic VEGF block-
ade was proposed to promote chondrogenesis at the expenses
of osteogenesis upon ectopic grafting of fetal bones or murine
skeletal stem cells [9, 10]. The soluble variants of VEGF recep-
tors (VEGF-Rs), namely soluble Flt-1 and Flk-1 (which are the
cleaved extracellular domains of VEGF-R1 and VEGF-R2, re-
spectively [11, 12]) are capable of acting as decoy receptors,
efficiently sequestering VEGF in the microenvironment of pro-
ducing cells and leading to blockade of VEGF signaling [13].
Previouswork indeed showed that the cartilage repair capacity
of skeletal muscle-derived stem cells genetically modified to
express bone morphogenetic protein (BMP)-4, a potent chondro-
genic inducer, could be improved by concomitant overexpression of
soluble Flt-1 in osteochondral defect [14] or osteoarthritis [15]
models.
In the present study, we addressed whether the simple inhi-
bition of angiogenesis by VEGF blockade is sufficient to direct in
vivo chondrogenic differentiation of implanted humanMSCs. The
hypothesis was tested in an ectopic environment that is permis-
sive, but not inductive of chondrogenesis [16, 17], and in the ab-
sence of any additional delivered chondrogenic morphogens.We
demonstrated that MSCs transduced to express sFlk-1 and di-
rectly implanted subcutaneously in nude mice without in vitro
preculture spontaneously differentiated into the chondrocytic
lineage. The resulting cartilagewas hyaline in nature and remained
phenotypically stable during the observation time of the study, up
to 12 weeks. In vitro studies revealed that the hypoxic environ-
ment, resulting from the blockade of angiogenesis, could directly
cause chondrogenic induction by stimulating activation of endog-
enous transforming growth factor (TGF) b signaling.
MATERIALS AND METHODS
Cell Isolation and Transduction
Bonemarrow aspirates were harvested from the iliac crest of five
healthy donors (four men and one woman; average age, 31 years
[range, 20–43 years]) during orthopedic surgical procedures, in
accordance with the local ethical committee and after provision
of informed consent. Freshly isolated bone marrow [18] was
plated at a density of 105 nucleated cells per cm2 and cultured
in high-glucose Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS; complete me-
dium) and5ng/ml fibroblast growth factor-2 tomaintainMSCdif-
ferentiation capacity [19, 20]. Six days after the first plating,
primaryMSCswere transducedwithpreviously described retrovi-
ral vectors, carrying the gene for themouseVEGF-R2 extracellular
domain (sFlk-1) fused to the IgG2a Fc domain (provided by C.J.
Kuo, Stanford University) [21], linked through an internal ribo-
somal entry site to a mouse truncated CD8a version [22, 23]. Na-
ı¨ve cells orMSCs transducedonlywith the truncatedmurine CD8a
were used as controls.
In Vitro Pellet Culture Model
MSCstransducedforsFlk-1andcontrolcellswereculturedfor2weeks
in pellets, as previously described [24], with serum-freemedium sup-
plementedwith 10 ng/ml of TGFb3 or without TGFb3. Unless other-
wise stated, all cultures were performed at 20% oxygen tension.
Cell-Based Construct Preparation and
Ectopic Implantation
A type I collagen sponge (Ultrafoam, Bard, Davol Inc.,Warwick, RI,
https://www.davol.com/) of 4-mm thickness was punched into
6-mm diameter disks, each of which was statically seeded with
1.73 106MSCs (density of 1.53 107 cells per cm3). The constructs
were cultured overnight with DMEM supplemented with 10% FBS
and 1% penicillin-streptomycin before implantation.
Four cell-based constructs were implanted subcutaneously
foreachnudemouse (CD-1nude/nude,6–8weeksold;CharlesRiver,
Germany, ).ThemiceweresacrificedwithCO2at1,4,8,and12weeks
after the implantation. Before sacrifice, mice were injected with
pimonidazole hydrochloride (Hydroxyprobe, Inc., Burlington, MA,
http://www.hypoxyprobe.com)at4weeksafter implantation.Allan-
imalswerecared forandprocessedaccording to theguidelinesof the
Cantonal Veterinary Office (Basel, Switzerland) for the care and use
of laboratory animals. Eachanalysiswasperformed independently in
four engineered tissues for each MSC primary.
Flow Cytometry
Transduced cells were analyzed for CD8a (sFlk-1-expressing or con-
trol CD8a-expressing MSC) by staining with an allophycocyanin-
conjugated anti-mouse CD8a (clone 53–6.7; BD Biosciences, San
Jose, CA, http://www.bdbiosciences.com) [23].
Enzyme-Linked Immunosorbent Assay
MSCs cultured in 60-mm dishes were incubated with 1 ml of cul-
turemedium for 4 hours. The supernatants were filtered through
0.45-mm syringe filters and frozen. Soluble mouse Flk-1 and
human VEGF production were quantified in cell culture superna-
tants using species-specific Quantikine immunoassay enzyme-
linked immunosorbent assay kits (R&D Systems, Abingdon, UK,
https://www.rndsystems.com/).
Biochemistry
Engineered tissues cultured in vitro for 3weekswere analyzed for
content of glycosaminoglycan (GAG) and DNAmeasured spectro-
photometrically using dimethylmethylene blue [25, 26] and the
CyQUANT Kit (Thermo Fisher Scientific Life Sciences, Waltham,
MA, http://www.thermofisher.com) [27], respectively.
Quantitative Real-Time Reverse Transcriptase-
Polymerase Chain Reaction
Total RNAof cellswasextractedbyusing Trizol (ThermoFisher) and
the standard single-step acid-phenol guanidinium method. RNA
was treated with DNAse-I using the DNA-free Kit (Thermo Fisher).
cDNAwas generated from 3mg of RNA by using 500mg/ml random
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primers (Promega, Wallisellen, Switzerland, http://www.promega.
com) and 1 ml of 50 U/ml Stratascript reverse transcriptase (Strata-
gene, Agilent Technologies, Basel, Switzerland, http://www.agilent.
com), in the presence of deoxynucleotides. Real-time reverse tran-
scriptase- polymerase chain reactions were performed and moni-
tored using the ABI Prism 7700 Sequence Detection System
(Thermo Fisher), and the gene expression data for all tested genes
(types II and X collagen [COL2A1 and COL10A1], Gremlin [GREM1],
TGFb1, and Indian Hedgehog [IHH]) were normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
HUVEC Proliferation and Human Dermal Microvascular
Endothelial Cell Tube Formation In Vitro Assays
Humanumbilical vein endothelial cell (HUVEC) proliferation assay
was performed as previously described by Centola et al. [28].
Briefly, supernatantswere collected fromcontrol and sFlk-1MSCs
after 48 hours in monolayer culture and stored at 220°C until
analysis. HUVECs were cultured in 96-well plates at a density of
5 3 103 cells per well in growth medium (M199 supplemented
with 20% FBS, 100 mg/ml endothelial cell growth supplement,
50 IU/ml heparin, 100 IU/ml penicillin, and 100mg/ml streptomy-
cin) for an initial 2 days and in low-FBS medium (assay medium,
consisting of M199 with 5% FBS, 10 IU/ml heparin, and 1%
penicillin/streptomycin), supplemented with recombinant human
VEGF (R&D Systems) at different concentrations (0–20 ng/ml),
mixed inequal volume to the supernatants for the following2days.
HUVEC metabolic activity was measured by MTS assay (Cell Titer
96, Promega). Data are presentedbyusing optical density arbitrary
units, from n = 3 independent specimens.
In vitro tube formation assaywas performedwith human der-
mal microvascular endothelial cells (HDMECs) as previously de-
scribed [29], either by using control or sFlk-1 MSC conditioned
media (Endothelial Cell BasalMediumMV [PromoCell, Heidelberg,
Germany, http://www.promocell.com/] with 5% FBS and 1%
penicillin-streptomycin solution) extracted after 48 hours or by di-
rect coculture of control or sFlk-1 MSC. Tube-like structures were
visualized with CD31 staining (Dako, Glostrup, Denmark, http://
www.dako.com) and a secondary goat anti-mouse antibody (Alexa
Fluor 488, Thermo Fisher); nuclei were stainedwithHoechst 33342
(Sigma-Aldrich, St. Louis, MO, http://www.sigmaaldrich.com/).
Histology
Engineered tissues were fixed with 4% formaldehyde and embedded
in paraffin or optimal cutting temperature medium. Paraffin sections
(5mmthick)werestainedforSafranin-Oandforimmunohistochemistry
for types II and X collagen, bone sialoprotein, and metalloproteinase-
13 (MMP-13). Histological sections stained for CD31 [30] were an-
alyzed for vessel quantification in the total implantation bed area
using NIS-Elements 4.0 software (Nikon Instruments Inc., Melville,
NY, https://www.nikoninstruments.com). The vessel number was
then normalized to area, with values reported as vessels/mm2.
Cryosections (10 mm thick) were incubated with the primary
antibodies pan human antinuclei (BD Pharmingen, Franklin Lakes,
NJ,http://www.bd.com)andwithasecondaryantibody labeledwith
AlexaFluor546(ThermoFisher).49,6-Diamidino-2-phenylindolewas
used as nuclear staining.
Histological Scoring System
The proposed histological score system for the assessment of the
quality of in vivo engineered cartilage tissues derives from a
modification of the categories published by Centola et al. [28].
Scoring rates are assessed blindly by three different observers.
Intensitydescribes theuniformityanddarknessof SafraninO-fast
green stain: no stain, 0; weak staining of poorly formed matrix, 1;
moderately even staining, 2; even dark stain, 3.
Density represents thedistance between cells/amount ofma-
trix: high cell densitieswith nomatrix in between, 0; high cell den-
sities with little matrix in between, 1; moderate cell density with
matrix, 2; low cell density with moderate distance between cells
and an extensive matrix, 3.
Morphology represents the cell appearance: condensed/
necrotic/pycnotic bodies, 0; spindle/fibrous, 1; mixed spindle/
fibrous with rounded chondrogenic morphology, 2; majority
rounded/chondrogenic, 3.
Calcifications observed by alizarin red staining within the car-
tilage newly formed: strong presence of abnormal calcifications
inside the neo-formed cartilage, 0; presence of some calcification
spots inside the newly formed cartilage, 1; presence of very few
calcification spots inside the repaired cartilage, 2; complete ab-
sence of calcifications throughout the newly formed cartilage, 3.
Final score classifies the following:
c Not-formed cartilage (mainly fibrotic tissue): 0–6
c Inhomogeneous and fibrocartilaginous tissue, with few and
nonconnected areas of newly formed cartilage: 6.1–11
c Good cartilaginous tissue, covering less than 60% of the tissue
cross-sectional area: 11.1–15
c Very good quality and homogeneity of newly formed cartilage:
15.1–18
Statistical Analysis
Datawereanalyzedwith the statistical softwarePrism5.0 (GraphPad
Software Inc., La Jolla, CA,http://www.graphpad.com/), using one-
way analysis of variancewith Bonferroni correction. (In the figures,
p indicatesp, .05 andpp indicatesp, .01.) Data are presented as
mean6 SD.
RESULTS
Transduced MSCs Maintain Their Proliferation and
Differentiation Capacity
MSCs were transduced with retroviruses expressing sFlk-1 to-
gether with a truncated version of mouse CD8a, used as a conve-
nient marker sortable by fluorescence activated cell sorting as
described elsewhere [22], or CD8a alone as a control,with a trans-
duction efficiency of 82%6 7% and 89%6 3%, respectively. Ge-
netically modified MSCs released 1.37 6 0.14 ng/106 cells of
mouse sFlk-1 per day. Consistent with our previous findings
[23], transduction caused a slight, not statistically significant, re-
duction in MSC proliferation during the first 2 passages (total cell
doublings in14days: na¨ıve,5.660.5;CD8a,4.560.8; sFlk-1, 3.96
0.2; p = N.S.). MSC chondrocytic differentiation in vitro, in the
presence of TGFb3, was not impaired by transduction (GAG/DNA
ratio: na¨ıve, 10.3 6 6.1; CD8a, 10.6 6 10.1; sFlk-1, 17.7 6 14.8;
p=N.S.) (supplementalonlineFig.1A). In theabsenceofTGFb3sup-
plementation, no chondrogenesis was observed in any population
(supplemental online Fig. 1A). Pellets by na¨ıve and CD8aMSCs also
released similar amounts of VEGF, at both 20% and 2% oxygen
(supplemental online Fig. 1B). On the basis of these results, in sub-
sequent experiments only na¨ıve MSCs were used as controls.
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Interestingly, although VEGF protein was strongly reduced in the
supernatants of sFlk-1 constructs at both 20% and 2% oxygen
(supplemental online Fig. 1B), VEGF expression at the mRNA level
was not downregulated in sFlk-1 constructs at either oxygen per-
centage (values ranging from 0.05- to 0.18-fold of GAPDH), con-
firming the potency of sFlk-1 in sequestering released VEGF.
sFlk-1 MSCs Inhibit Angiogenesis In Vitro
The biological activity of sFlk-1 MSCs to block VEGF-induced an-
giogenesis was first tested in vitro. Supernatants conditioned
by sFlk-1 MSCs for 48 hours inhibited proliferation of HUVECs in-
duced by VEGF concentrations up to 10 ng/ml (Fig. 1A), showing
that sFlk-1 produced by transduced cells was biologically active.
Because sFlk-1 works by competitive inhibition, the effect could
be overcome by very high VEGF concentrations (20 ng/ml).More-
over, the direct coculture of HDMECs with sFlk-1 MSC blocked
the in vitro formation of capillary-like structures compared with
control MSCs (Fig. 1B). Effective inhibition was confirmed with
conditioned media in the absence of MSCs: sFlk-1 secreted by
transducedMSCs substantially reducedHDMECorganization into
tubular structures in a three-dimensional (3D) collagen/fibrin gel-
based culture model compared with control supernatants (Fig.
1C), as shown by the decreased tube number and length, as well
as by the lower branching points and number of loops (Fig. 1D).
The effects of 10 ng/ml of VEGFwere completely abolished, while
they were reduced with 50 ng/ml, showing a dose-dependent
blockade by sFlk-1.
sFlk-1 MSCs Inhibit Angiogenesis In Vivo
Control or sFlk-1 MSCs were then loaded into collagen sponges
and immediately implanted subcutaneously in nude mice for as-
sessment of vascularization. After 12 weeks, control constructs
appeared macroscopically vascularized, whereas sFlk-1 implants
were predominantly avascular, with some blood vessels visible
only in discrete peripheral regions (Fig. 2A). Quantification of ves-
sels after CD31 immunohistochemical staining in the total area of
Figure 1. Inhibitory effect of sFlk-1 expressed by bone marrow-derived mesenchymal stromal/stem cells (MSCs) on in vitro endothelial orga-
nization and proliferation. Human umbilical vein endothelial cell proliferation assay performed by using supernatants collected by na¨ıve (con-
trol) or sFlk-1-expressing MSCs. (A): Cell metabolic activity was measured on the basis of the colorimetric MTS assay and represented by using
optical density units. (B): Immunofluorescence staining forCD31 in green showing the capillary-like structure formation in thedirect cocultureof
either control or sFlk-1-expressing MSCs with human dermal microvascular endothelial cells. (C): Representative images of tubular structure
formation of endothelial cells (stained with calcein assay medium in green after 48 hours) cultured in medium conditioned by control or sFlk-1
expressingMSCs supplementedwith 0, 10, or 50ng/ml ofVEGF. Scale bars =300mm. (D):Total tubenumber, length, branching points, and loops
were quantified by image analysis. Ten images per sample were analyzed. Data are presented as mean6 SD (n = 4 samples/group from 2 in-
dependent experiments). p, p , .05; pp, p , .01. Abbreviations: OD, optical density; VEGF, vascular endothelial growth factor.
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explanted tissues indicated a greatly reduced vessel density with
sFlk-1MSCs comparedwith control cells throughout the 12-week
observation time (Fig. 2B). Histological analysis revealednovessel
infiltrationwithin the actual sFlk-1 constructs up to 12weeks (Fig.
2C), whereas the few vessels that could be quantified were con-
fined in the surrounding connective tissue at the periphery of the
implant. To the contrary, constructs based on control MSCs dis-
played vessel ingrowth up to the center of the implants already
after 1 week, further progressing until 12 weeks (Fig. 2C).
sFlk-1 MSCs Undergo Spontaneous Chondrogenesis In
Vivo Without Hypertrophy
Histologically, no cartilage formation was observed in collagen
sponges loaded with control MSCs from any of the five donors
tested, at any time point (Fig. 3A, 3B). Instead, implants based
on sFlk-1 MSC from the same donors displayed foci of chondro-
genesis in all cases. In these regions, cells acquired a typically
chondrocytic morphology within round lacunae, surrounded by
abundant extracellular matrix positively stained for both GAG
and type II collagen (Fig. 3A, 3B). Together, these features indicate
the hyaline, as opposed to fibrous, nature of the generated car-
tilage tissues [31]. Formation of cartilaginous structures was al-
ready visible by 4 weeks and further increased in quantity and
staining intensity by 12 weeks (supplemental online Table 1).
The newly formed cartilage only sporadically displayed foci of
calcification in scattered peripheral regions but was neither
resorbed nor remodelled into osteoid tissue. Immunofluores-
cence staining for human nuclei indicated that sFlk-1 MSCs per-
sisted in the formed cartilaginous tissue up to 12 weeks after in
vivo implantation, whereas control MSCs could be detected at
amuch lower frequencyup to4weeks invivo andanegligible frac-
tion survived by 12 weeks (Fig. 3A, 3B). The result is consistent
with the loss of implanted MSC not sufficiently preconditioned
in vitro with differentiating stimuli [3]. Interestingly, MSCs from
only 3 of the same 5 donors were capable of in vitro chondrogen-
esis in pellet cultures stimulated with the strong inducer TGFb3.
This indicates the robustness of spontaneous chondrogenesis en-
abled by VEGF blockade, despite the known interdonor variability
in the chondrocytic differentiation potential of MSCs.
After 12 weeks in vivo, cartilaginous constructs generated by
sFlk-1MSCs remainednegative formarkers of hypertrophic trans-
formation, namely type X collagen and bone sialoprotein (Fig. 4).
Phenotypic stability was further confirmed by the absence of ex-
pression of MMP-13 (Fig. 4), a hallmark of cartilage remodeling
during endochondral ossification [3].
LowOxygen Tension TriggersMSCChondrogenesis Even
in the Absence of TGFb
Staining with pimonidazole hydrochloride (Hypoxyprobe-1), a
marker of hypoxia, indicated that cells in the tissues formed
by sFlk-1 MSCs were exposed to oxygen levels lower than 1%,
consistent with the absence of vascularization (supplemental
online Fig. 2). On the basis of this finding, we testedwhether hyp-
oxic conditions could trigger chondrogenesis in vitro and possibly
dispensewith the requirement for TGFb3 stimulation to differen-
tiate MSCs into chondrocytes. In the presence of TGFb3, na¨ıve
MSCs generated cartilaginous pellets, whose quality was inde-
pendent of oxygen tension, as shown by GAG and type II collagen
Figure 2. In vivoblockingofangiogenesis. (A):Representativemacroscopicpictureof theexplantsofengineered tissuegeneratedbyna¨ıve (left) or
sFlk-1-expressing (right)MSCs after 12weeks in vivo. (B):Vessel density quantifiedwithin the total area of the implant generated by control (na¨ıve)
or sFlk-1 MSCs at different time points by histomorphometric analysis (n = 3–4). p, p, .05. (C): Immunohistochemistry for mouse CD31. Repre-
sentative images at320magnification include the central implant area generated by naive (top row) or sFlk-1 (bottom row)MSCs at 1, 4, 8, or 12
weeks.Blackarrowheads indicate thebloodvessels. Scalebar=100mm.Abbreviation:MSC,bonemarrow-derivedmesenchymal stromal/stemcell.
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staining, as well as gene expression analysis (Fig. 5A, 5C). In the
absence of TGFb3, cells cultured in 20% oxygen generated only
fibrous tissue, whereas reduction of oxygen to 2% induced clear
foci of chondrogenesis after 2weeks of culture (n=3 independent
donors), as shownbypositive staining forGAGand type II collagen
(Fig. 5B) and a marked upregulation of type II collagen mRNA to
levels up to threefold higher than even in the conditions treated
with TGFb3 (Fig. 5D). Hypoxia-mediated induction of chondro-
genesis was also associated with the activation of the TGFb path-
way. In fact, not onlydid it causeamarked (350-fold) upregulation
of TGFb1 expression compared with 20% oxygen (Fig. 5D), but
type II collagen upregulation was prevented by treatment with
SB-431542, an inhibitor of the TGFb type I receptor activin
receptor-like kinase-5 (15-fold reduction). Hypoxic culture in
2% oxygen in the absence of TGFb3 stimulation also induced a
gene expression pattern supportive of a stable chondrocytic phe-
notype because it reduced expression of hypertrophic markers,
namely type X collagen and Indian Hedgehog, and it increased ex-
pression of Gremlin-1, which has a role in reducing hypertrophy
by blocking the BMP pathways [32]. To verify whether sFlk-1 ex-
pression might have a direct effect on the chondrogenic commit-
ment of MSCs, we compared their gene expression for collagen II
and TGFb1 to that of na¨ıve cells. In the absence of TGFb3 supple-
mentation andof hypoxia, sFlk-1MSCsdid not show increased ex-
pression of either gene compared with control MSCs (collagen II,
1.53 1025 6 2.51026 vs. 3 3 1024 6 2 3 1024; TGFb1, 2.63
1021 6 3 3 1022 vs 1.63 1021 6 1.23 1021).
DISCUSSION
In this study, we demonstrated that blocking VEGF signaling by
sFlk-1 overexpression in uncommitted humanMSCs results in ef-
ficient inhibitionof angiogenesis and in robust spontaneous chon-
drogenic differentiation in vivo. Hyaline-like cartilagewas already
formed after only 4 weeks and was maintained up to the last ob-
servation (12weeks)with featuresofphenotypic stability, despite
the otherwise intrinsic propensity ofMSC to reach a hypertrophic
phenotype and undergo endochondral ossification [2, 3].
It is well established that vascular regression during limb
mesenchymal cell condensation is required for chondrogenesis
[33] and that antiangiogenic peptides (e.g., endostatin/collagen
XVIII) play an important role for the development and mainte-
nance of cartilage [34]. In this context, our work provides the
Figure4. In vivo cartilage stability. Immunohistochemistry for typeX
collagen, BSP, andMMP-13on sections of hypertrophic cartilage gen-
erated in vitro by MSCs (as a positive control) and on sections of the
cartilaginous constructs generated in vivo by sFlk1MSCs 12weeks af-
ter implantation. Scale bar = 50 mm. Abbreviations: BSP, bone sialo-
protein;MMP-13,metalloproteinase-13;MSC, bonemarrow-derived
mesenchymal stromal/stem cell.
Figure 3. In vivo chondrogenesis. Histological staining with Safranin-O for glycosaminoglycans and immunohistochemistry for type II collagen
of engineered tissuegeneratedbyna¨ıve (control) or sFlk-1MSCsafter 4 (A)or12 (B)weeks in vivo. Fluorescence stainingwithDAPI (inblue) anda
specific anti-human nuclei antibody (in red) of constructs generated by control or sFlk-1 MSCs after 4 (A) or 12 (B)weeks in vivo. Scale bar =
100 mm. Abbreviations: DAPI, 49,6-diamidino-2-phenylindole; MSC, bone marrow-derived mesenchymal stromal/stem cell.
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unprecedented proof that the sole blockade of angiogenesis,
without the delivery of any exogenous morphogen, is sufficient
to robustly direct adult human mesenchymal progenitors into
the chondrogenic lineage. Previous studies, using murine muscle-
derived stem cells (MDSCs) engineered to sequester VEGF by over-
expressing soluble VEGFR-1 (sFlt-1), demonstrated enhanced
cartilage healing in osteochondral defect [15] or osteoarthritis
[14] models, but only if a potent chondrogenic morphogen (BMP-4)
was additionally delivered; in contrast, our data show spontaneous
chondrogenesis intheabsenceofanygrowthfactor treatment.This
discrepancymaybedueto(a) theas-yetuncontrolledcomplexityof
coupling progenitor differentiation with cartilage repair in a path-
ologic jointenvironmentand/or (b) a fundamental biological differ-
ence between the two species and classes of progenitors (human
MSCs vs. murine MDSCs).
Mechanistically, induction of MSC chondrogenesis by sFlk-1
overexpression could be explained by an indirect effect of inhibi-
tion of angiogenesis, or by a direct autocrine regulation, because
VEGF receptor is expressed by human MSCs [35] and immature
[36] as well as hypertrophic [4] chondrocytes. The in vitro exper-
iments in supplemental online Fig. 1 indicate that sequesteringVEGF
by sFlk-1 expression did not directly regulate the chondrogenic
capacity of MSCs, consistent with a previous report using MDSC-
releasing sFlt-1 [15]. Because one of the immediate consequences
of inhibition of angiogenesis is the generation of a hypoxic environ-
ment, we investigated the effects of hypoxia in promoting in vitro
chondrogenesis. Low oxygen tension was previously shown to pro-
mote MSC proliferation and maintenance of a progenitor state
during monolayer expansion [37, 38], as well as to enhance TGFb-
induced chondrogenesis during 3D culture of MSCs [17, 37–41].
To the best of our knowledge, here we provide the first demonstra-
tion that reductionof theoxygen tension from20%to2% is sufficient
to primeMSC chondrogenesis in vitro, in the absence of any exoge-
nously supplemented morphogen. Combined with the proof that
hypoxia is established in the implanted constructs in vivo and that
sFlk1 does not directly affect chondrogenesis in vitro in 20% oxygen
conditions, these findings strongly suggest that VEGF blockade
primes MSC to form cartilage indirectly by inhibiting angiogenesis
and generating a hypoxic environment. Analysis of TGFb expression
and inhibitionofTGFb signaling further suggest that thehypoxic con-
ditions activated chondrogenesis by inducing TGFb upregulation, as
recently observed in a chondrocyte culture model [42], thereby dis-
pensing with the need to provide stimulation with exogenous mor-
phogens. Further studiesare required todefine the temporal kinetics
Figure 5. In vitro chondrogenesis at different oxygen tensions. Histological staining with Safranin-O and immunohistochemistry for type II
collagen on constructs generated in vitro by na¨ıveMSC culturedwith (A) orwithout (B) TGFb3 supplementation at 2%or 20%of oxygen tension.
Scale bar = 50mm. Expression levels of themRNA for type II and X collagen, Gremlin-1, IHH TGFb1were quantified in pellets generated by na¨ıve
bone marrow-derivedmesenchymal stromal/stem cells (C, D) cultured in the two different oxygen tensions. ΔCt values were normalized
to expression of the GAPDH housekeeping gene, and results are shown as mean6 SD (n = 6 samples/group from 3 independent exper-
iments). p, p , .05, ppp, p , .001. Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IHH, Indian hedgehog; TGFb,
transforming grown factor-b.
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of TGFb production at the protein level and whether possibly in-
creased quantities would be found embedded within the deposited
extracellular matrix or released in the culture medium.
The cartilage tissue formed in vivo by sFlk-1 MSCs did not de-
velop hypertrophy up to 12 weeks after implantation and dis-
played no signs of endochondral ossification, which otherwise
occurs spontaneously in the samemodel [3]. This result was mir-
rored by the gene expression pattern consistent with a stable
chondrocytic phenotype reached by MSCs cultured in hypoxic
conditions in vitro and in the absence of TGFb3, with basal levels
of type X collagen and Indian Hedgehog. Interestingly, we also
found that the chondrogenic effect of hypoxia was associated
with the activation of the TGFb pathway and with the upregula-
tion of Gremlin-1, an inhibitor of BMP signaling. On the basis of
developmental events occurring in early limb mesenchyme [43]
and recent findings reported by using adult human MSCs [40],
the combination of these twomolecular settings provides a plau-
sible explanation for the observed induction of chondrogenesis in
the absence of hypertrophy.
A reduced delivery of specific nutrients could also have con-
tributed to the triggering of MSC chondrocytic differentiation
upon inhibition of angiogenesis. For example, limited availability
of glucose could have forced its reduced consumption, which
physiologically parallels chondrogenesis by mesenchymal pro-
genitors [38]. Moreover, reduced vascularization implies that
MSCs would not be exposed to possible inhibitors of chondro-
genesis present in serum or released by platelets [44, 45], as
well as to proinflammatory factors (e.g., interleukin-1b) pro-
duced by ingrowing granulation cells [46] and known to be det-
rimental for chondrocyte differentiation and cartilage formation
[47]. Similarly, the absence of remodeling of the resulting carti-
lage into bone tissue could be mediated by the impairment
of monocytes/chondroclasts, whose recruitment, differentia-
tion, and activity are known to be dependent on VEGF [48, 49].
Although these alternative and possibly concomitant mecha-
nisms cannot be excluded, our data point to the key role of hyp-
oxia and TGFb upregulation in mediating the effect of sFlk-1
overexpression.
From a translational perspective, our findings are relevant for
new therapeutic approaches to articular cartilage repair, based
on the generation of an avascular environment for resident or
implantedMSCs. Tomove in this direction, further studies are re-
quired to test sFlk-1 MSCs in a cartilage repair model mimicking
the biological (e.g., inflammatory component) and physical (e.g.,
mechanical loading) complexity of a joint environment [50] and
with a longer observationperiod.Moreover, safety issues, related
to the use of genetically modified MSCs, need to be addressed.
For example, sustained stable expression of a transgene could
be obtained by using self-inactivating lentiviral vectors, with
the great advantage of decreasing the oncogenic potential as
compared with retroviral ones [51, 52]. Alternatively, the thera-
peutic strategy could be implemented by a scaffold-based deliv-
ery of humanized monoclonal anti-VEGF antibodies, as recently
described for the enhanced formationof cartilagebyhumannasal
chondrocytes [28].
CONCLUSION
Fromabroader biological perspective, our studyoutlines the gen-
eral paradigm to induce a specific differentiation of MSCs by en-
gineering their intrinsic capacity to modify and control key
features of the site of implantation. This would in turn result in
MSC exposure tomultiplemicroenvironmental regulatory signals
andwould thus differ from the typical direct delivery of individual
morphogenic cues. The concept, underpinning the critical mutual
interactions occurring between grafted cells and the host envi-
ronment and possibly targeting the artificial recapitulation of
developmental events in an adult organism [53], was here exem-
plified in the context of angiogenic signals, but it couldbeextended
tootherstemorprogenitor cell systems,aswell as toother features
of the recipient site.
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